• Home
• bybest fajas
• First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

5 (148) · $ 18.99 · In stock

Acetyl-CoA metabolism as a therapeutic target for cancer

Acetyl-CoA metabolism as a therapeutic target for cancer

Fatty acids in cancer chemoresistance - ScienceDirect

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640

PDF) Metabolic dysregulation and emerging therapeutical targets

Acetyl-CoA metabolism as a therapeutic target for cancer

Acetyl-CoA metabolism as a therapeutic target for cancer

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Emerging roles of fatty acid metabolism in cancer and their

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein